Publications by authors named "Ellen M Apperloo"

Claim this Profile
G
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.
Ellen M Apperloo, Hiddo J L Heerspink, Daniël H van Raalte, Marcel H A Muskiet

Nephrol Dial Transplant· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
Ellen M Apperloo, Katherine R Tuttle, Imre Pavo, Axel Haupt, Rebecca Taylor

Diabetes Care· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.
Ellen M Apperloo, Hiddo J L Heerspink, Annemarie B van der Aart, Dennis Rouw, Daniël H van Raalte

Diabetes Care· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.
Ellen M Apperloo, David Z I Cherney, Anja Birk Kuhlman, Johannes F E Mann, Søren Rasmussen

Nephrol Dial Transplant· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
Ellen M Apperloo, Jose L Gorriz, Maria Jose Soler, Secundino Cigarrán Guldris, Josep M Cruzado

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Ellen M Apperloo, Brendon L Neuen, Robert A Fletcher, Niels Jongs, Stefan D Anker

Lancet Diabetes Endocrinol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.
Ellen M Apperloo, Michelle J Pena, Dick de Zeeuw, Petra Denig, Hiddo J L Heerspink

Diabetes Obes Metab· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis